Introduction {#Sec1}
============

In 1994, the Revised European-American Lymphoma (REAL) Classification introduced new standards in the lymphoma field \[[@CR1]\]. In particular, it stated for the first time that a classification of lymphoid tumors should comprise a list of "real" entities, each defined by the amalgamation of cell morphology, phenotype, molecular genetics, clinical data, and identification of a normal counterpart, if possible \[[@CR1]\]. After a validation trial \[[@CR2]\], the REAL Classification was adopted by the World Health Organization (WHO) as guideline for lymphoma diagnosis and therapy, and its methodology was extended to all tumors of the hematopoietic system \[[@CR3]••\]. Based on patients' survival without any treatment, non-Hodgkin lymphomas (NHLs) are classified as indolent (survival measurable in years) or aggressive (survival measurable in months).

Peripheral T-cell lymphomas (PTCLs) belong to the aggressive lymphoma group \[[@CR4]••\]. They represent approximately 12% of all lymphoid neoplasms \[[@CR4]••, [@CR5]••\]. Their incidence varies in different countries and races, being higher in HTLV-1 endemic areas (Asia, the Caribbean basin, and some parts of the United States) \[[@CR4]••, [@CR5]••\]. PTCLs are a heterogeneous group of tumors that can be roughly subdivided into specified and not otherwise specified (NOS) forms \[[@CR5]••, [@CR6]•\]. The NOS forms, corresponding to about 60% to 70% of T-cell lymphomas, cannot be further classified on the basis of morphology, phenotype, and conventional molecular studies \[[@CR4]••\]. Usually, they occur in the fifth or sixth decade of life, without sex predilection \[[@CR7]--[@CR10]\]. Although PTCLs/NOS can present as isolated disease, they more often have a widespread dissemination (stage III--IV) with nodal, skin, liver, spleen, bone marrow, and peripheral blood involvement \[[@CR7]--[@CR10]\]. B symptoms are recorded in about 45% of cases at diagnosis. A hemophagocytic syndrome may also be encountered \[[@CR7]--[@CR10]\].

The tumor morphology is highly variable, comprising cells of different sizes and shapes \[[@CR4]••\]. PTCLs/NOS may contain prominent reactive components, including small lymphocytes, eosinophils, plasma cells, histiocytes, and epithelioid elements \[[@CR4]••\].

Immunohistochemistry generally shows T-cell-associated molecular expression, but the phenotypic profile is aberrant in about 80% of cases \[[@CR11]\].

Clonal rearrangements of T-cell receptor encoding genes are generally detected \[[@CR12]\]. The karyotype is aberrant in more than 80% of patients and often is characterized by complex abnormalities. However, specific alterations have not been identified \[[@CR13]\]. Recently, some recurrent lesions have been documented by comparative genomic hybridization and analysis of single-nucleotide polymorphisms (SNPs) \[[@CR14], [@CR15]\].

On clinical grounds, PTCLs/NOS are among the most aggressive NHLs. In most cases, the response to conventional chemotherapy is indeed frustrating, with rates of relapse-free and overall survival (OS) at 5 years less than 30% \[[@CR5]••\]. Notably, histologic classification remains a basic prognostic indicator \[[@CR5]••, [@CR6]•, [@CR8], [@CR16]\]. Nodal and extranodal entities are clinically distinct, as extranodal tumors, especially the cutaneous forms, often have a relatively good outcome \[[@CR5]••\]. In addition, among nodal PTCLs, the distinction between anaplastic large-cell lymphoma (ALCL) and other entities retains a significant prognostic impact, as does the distinction between anaplastic lymphoma kinase-positive (ALK^+^) and ALK^−^ cases among ALCLs, \[[@CR5]••, [@CR6]•, [@CR8], [@CR16]\]. In fact, patients with ALK^+^ ALCL, particularly children and young adults, have a significantly better clinical outcome than patients with all other forms \[[@CR5]••, [@CR6]•\]. Importantly, it was recently suggested that ALK^−^ ALCL should be included in PTCLs/NOS, based on a lack of evidence of clear biologic differences between them, but new clinical and molecular findings have demonstrated that ALK^−^ ALCL and PTCL/NOS are distinct entities, also presenting with different clinical outcomes \[[@CR6]•, [@CR17]••, [@CR18]\].

In addition to the basic distinction of the different entities, several attempts have been made in recent years to offer reliable prognostic indicators. Clinical, pathological, clinical-pathological, and molecular scores have been proposed and are briefly discussed in this article (Table [1](#Tab1){ref-type="table"}). Table 1Prognostic markers and scores in peripheral T-cell lymphomas (PTCLs)Prognostic indicatorPTCL subtypeStudiesHistotypeAllThe Non-Hodgkin's Lymphoma Classification Project \[[@CR2]\]; Vose et al. \[[@CR5]••\]; Savage et al. \[[@CR6]•\]; Lopez-Guillermo et al. \[[@CR8]\]; Ascani et al. \[[@CR16]\]International Prognostic Index (IPI)AllThe Non-Hodgkin's Lymphoma Classification Project \[[@CR2]\]ALCLSavage et al. \[[@CR6]•\]; Falini et al. \[[@CR20]\]ATLLSuzumiya et al. \[[@CR21]•\]NK/T-cell lymphomaAu et al \[[@CR57]•\]PITPTCL/NOSGallamini et al. \[[@CR22]\]; Savage et al. \[[@CR6]\]Bologna scorePTCL/NOS, AITLWent et al. \[[@CR11]\]; Briones et al. \[[@CR34]\]Korean prognostic indexNK/T-cell lymphomaLee et al. \[[@CR54]\]NK prognostic indexNK/T-cell lymphomaSuzuki et al. \[[@CR67]\]EBVPTCL/NOS, AITLWent et al. \[[@CR11]\]; Kluin et al. \[[@CR24]\]; Dupuis et al. \[[@CR25]\]NK/T-cell lymphomaAu et al. \[[@CR62]\]; Cheung et al. \[[@CR60]\]; Chim et al. \[[@CR64]\]; Huang et al. \[[@CR65]\]; Lee et al. \[[@CR66]\]; Ng et al. \[[@CR63]\]Proliferation indexPTCL/NOSKi-67Went et al. \[[@CR11]\]Molecular signatureCuadros et al. \[[@CR43]•\]Cellular derivationPTCL/NOSWent et al. \[[@CR11]\]^a^; Bekkenk et al. \[[@CR26]\]; Kojima et al. \[[@CR27]\]; Iqbal et al. \[[@CR48]•\]NFκB activationPTCL/NOSMartinez-Delgado et al. \[[@CR36]\]; Ballester et al. \[[@CR38]\]; Briones et al. \[[@CR34]\]CYP3APTCL/NOSRodríguez-Antona et al. \[[@CR49]\]*AITL* angioimmunoblastic T-cell lymphoma; *ALCL* anaplastic large-cell lymphoma; *ATLL* adult T-cell leukemia/lymphoma; *NK* natural killer; *PTCL/NOS* peripheral T-cell lymphoma not otherwise specified^a^Prognostic impact not statistically significant

International Prognostic Index (IPI) {#Sec2}
====================================

The International Prognostic Index (IPI) was first introduced in 1993 with the intent of identifying patients affected by aggressive NHL, with its greater risk of treatment failure, relapse, and death \[[@CR19]\]. It is based on clinical parameters, such as tumor stage, extranodal localization, age, lactate dehydrogenase (LDH) level, and performance status. It was largely based on B-NHL rather than T-NHL, especially diffuse large B-cell lymphomas (DLBCLs), but its ability to stratify PTCL patients was reported in later years. In particular, the International Lymphoma Study Group showed that OS and relapse-free survival were significantly different in patients with low IPI (0/1) versus high (4/5) IPI for all PTCL types except ALCL (5-year OS, 36% vs 15%; 5-year failure-free survival, 27% vs 10%) \[[@CR2]\]. On the other hand, subsequent studies showed that the IPI was particularly effective for prognostication in both ALK^+^ and ALK^−^ ALCL \[[@CR6]•, [@CR20]\]. In particular, in ALK^+^ ALCL, the 5-year OS was 94% ± 5% for the low/low-intermediate risk group versus 41% ± 12% for the high/high-intermediate group (*P* \< 0.0001) \[[@CR20]\]. In fact, the IPI was more relevant than ALK expression in stratifying patients with ALCL: the relative risk of death was 3.50 for the high/high-intermediate IPI group versus 0.29 for the low/low-intermediate group, though both the IPI score and ALK expression were significant prognostic factors \[[@CR20]\]. In addition, in a large study within the International T-cell Lymphoma Project (ITCLP), the IPI effectively identified risk groups with different prognoses within both ALK^+^ and ALK^−^ ALCL, although those with an IPI score of 3 or more fell into the poor-risk category regardless of ALK status \[[@CR6]•\].

Furthermore, Suzumiya et al. \[[@CR21]•\] recently reported on a large series of patients with aggressive adult T-cell leukemia/lymphoma (ATLL), providing evidence that IPI, platelet count, and B symptoms were significant prognostic factors. Interestingly, multivariate analysis indicated that only the IPI was an independent predictor of OS in this series, though the IPI prediction of OS was significant only for the lymphoma type of ATLL (*P* = 0.04), not for the acute type (*P* = 0.24) \[[@CR21]•\].

Overall, IPI identification of patients at higher risk is the expression of disease extension and the patient's frailty. It offers neither specific biologic hints nor potential targets for overcoming drug resistance. It soon became clear that the IPI was not as effective in PTCLs/NOS and angioimmunoblastic T-cell lymphomas (AITLs) (the two commonest PTCL types) as in the original series of DLBCLs, probably reflecting, at least in part, the fact that PTCL therapy is basically derived from B-NHLs and specific trials have been lacking for a long time. Thus, novel prognostic scores for PTCLs have been investigated in the past few years.

Prognostic Index for PTCL/NOS {#Sec3}
=============================

In 2004, an Italian group (Intergruppo Italiano Linfomi) proposed a novel prognostic model based on a retrospective, multicentric clinical analysis of 385 patients with PTCL unspecified (PTCL-U) \[[@CR22]\]. The new model, the Prognostic Index for PTCL-U (PIT), included bone marrow involvement, age, performance status, and LDH. When these four variables were combined in four groups, the PIT could identify patient subgroups with different outcomes. The PIT turned out to be slightly more effective than the IPI in stratifying PTCL patients (log-rank 66.79 vs 55.94) and was then proposed as reference tool. In addition, a simplified, two-class PIT appeared to be superior to a simplified two-class IPI (log-rank 49.36 vs 30.23) \[[@CR22]\]. However, the PIT was based on a series lacking systematic histologic review and, although its value was confirmed within the International Peripheral T-Cell Lymphoma Project (ITCLP), its results were not superior to those of the IPI. In particular, the PIT was also applied to ALK^+^ and ALK^−^ ALCL and was similarly predictive of failure-free survival and OS in both groups \[[@CR6]•\]. However, given that the distribution of patients across the risk groups was very similar with the two prognostic models and that bone marrow involvement is rarely observed in ALCL, the PIT actually seems to mirror the IPI in this setting \[[@CR6]•\]. In addition, as it does not include tumor-specific biologic factors, cannot be intended for the future application of targeted therapies.

Clinical-Pathologic Prognostic Score (Bologna Score) {#Sec4}
====================================================

Immunohistochemical markers have been largely proposed for prognostication of malignant lymphomas. In a large collection of Italian PTCL cases, Went et al. \[[@CR11]\] found that high Ki-67 expression, positive Epstein-Barr virus (EBV) status, and CD15 staining were associated with the worst outcome in PTCL/NOS. Interestingly, EBV has repeatedly been proposed as a negative prognosticator in PTCLs \[[@CR23]\], among both Asian and European patients \[[@CR24], [@CR25]\]. Specifically, Went et al. \[[@CR11]\] found EBV positivity in 5% of patients with PTCL/NOS and 3% of those with AITL, values definitely lower than the value recorded by Dupuis et al. \[[@CR25]\] in a French PTCL cohort. Such discrepancies may reflect geographic or racial differences. No other immunohistochemical marker alone or in combination was associated with a poor outcome, although patients with tumors expressing CD57 or CD4^+^/CD8^−^ phenotype showed a tendency for a better outcome; the possible prognostic relevance of the latter phenotype has also been proposed by others \[[@CR26], [@CR27]\].

Furthermore, based on a large series provided with follow-up data, Went et al. \[[@CR11]\] developed a new score integrating both patient-specific and tumor-specific characteristics (age \>60 years, performance status, LDH, and Ki-67 protein ≥80%) and identifying three clearcut groups of patients with different responses to therapy and differing life expectancy (median OS, 37 vs 23 vs 6 months; *P* \< 0.001) \[[@CR11], [@CR22], [@CR28]--[@CR33]\]. This score, the Bologna score, seemed to be better able to predict patient outcome than previous indices, including the IPI (*P* \< 0.001 vs 0.1) and PIT (*P* \< 0.001 vs 0.0043). The prognostic ability of the Bologna score was recently validated by a Spanish group \[[@CR34]\]. Remarkably, all the factors contributing to the scoring system proposed by Went et al. \[[@CR11]\], which incorporates both patient-specific and tumor-specific characteristics, are part of the routine workup, making their integration simple and cost-effective.

Gene Expression Profiling {#Sec5}
=========================

In the past few years, numerous studies have dealt with the gene expression profiling (GEP) of nodal PTCLs \[[@CR17]••, [@CR18], [@CR35]--[@CR38], [@CR39]••, [@CR40]••, [@CR41], [@CR42], [@CR43]•, [@CR44]--[@CR47], [@CR48]•\], possibly providing novel insight into PTCL prognostication. First, a few reports suggested that PTCLs/NOS may present with upregulation or downregulation of NFκB molecules \[[@CR35], [@CR36], [@CR38]\], with possible prognostic relevance \[[@CR36], [@CR38]\]. In particular, cases with lower levels of NFκB-related molecules or other evidence of NFκB inactivity showed better survival, with a median OS of 25 months (range 0--124 months) versus a median OS of 12 months (range 0--19 months) (*P* = 0.032) \[[@CR36], [@CR38]\]. This observation was confirmed by another Spanish group, which demonstrated 5-year OS of 45% in NFκB^+^ cases versus 0% in NFκB^−^ cases (*P* = 0.04) \[[@CR34]\]. However, all these studies included a relatively limited number of cases, mixed different histotypes \[[@CR34], [@CR36]\], or included patients with prominent nonneoplastic components \[[@CR38]\], which may have influenced the results, at least in part.

In addition, based on GEP obtained from 35 patients with nodal PTCL (23 with PTCL/NOS and 12 with AITL), it was suggested that overexpression of genes involved in a "proliferation signature" was associated significantly with shorter survival \[[@CR43]•\]. This proliferation signature included genes commonly associated with the cell cycle, such as *CCNA*, *CCNB*, *TOP2A*, and *PCNA* \[[@CR43]•\]. Notably, this evidence of high proliferation as a possible adverse prognostic factor was definitely in line with the findings of Went et al. \[[@CR11]\] and the ITCLP (unpublished), highlighting the importance of this parameter.

Finally, based on GEP analyses, our group indicated that PTCLs/NOS can be subclassified on the basis of histogenesis. In particular, at least two subgroups were described, derived from activated helper elements and cytotoxic elements \[[@CR17]••\]. This finding was recently confirmed by Iqbal et al. \[[@CR48]•\]. Intriguingly, this report also suggested that the cytotoxic profile may be associated with unfavorable outcome, though this evidence was based on a limited series and warrants further validation. On the other hand, the possibility of more favorable outcome for PTCL cases with a helper phenotype has been previously suggested by others \[[@CR11], [@CR26], [@CR27]\].

Overall, GEP studies have provided evidence that molecular features may be useful in defining the prognosis of PTCL patients. However, no complete explanation has been offered regarding the molecular basis of drug resistance. Our group described for the first time the expression of molecules associated with drug resistance in solid tumors, such as *CYR61* and *NNMT* in PTCL/NOS \[[@CR17]••\]. Furthermore, Rodríguez-Antona et al. \[[@CR49]\] recently found that a high expression of cytochrome P450 3A (CYP3A), an enzyme involved in the inactivation of chemotherapy drugs, was associated with poor response to standard PTCL chemotherapy, suggesting that CYP3A could be useful as a predictor of response. Indeed, the molecular classification of PTCLs and the identification of key events in their molecular pathology is likely to be the basis for future prognostication and targeted treatment in this field, as has occurred in DLBCL \[[@CR50], [@CR51]••\].

Prognostication of NK/T-Cell Lymphoma, Nasal Type {#Sec6}
-------------------------------------------------

Extranodal natural killer (NK)/T-cell lymphoma, nasal type is a distinct entity in the WHO classification of lymphoid tumors; it is more frequent in Asia and in Central and South America than in Western countries \[[@CR52]--[@CR56], [@CR57]•\]. Morphologically, tissue invasion, vascular destruction, and necrosis are the most prominent features; EBV is always integrated in the genome of neoplastic cells \[[@CR56]\]. Most cases derive from NK cells and are characterized by a typical NK phenotype and T-cell receptor genes in germ-line configuration, but in some instances a cytotoxic T-lymphocyte origin has been recognized \[[@CR56]\]. The nasal cavity and the upper aerodigestive tract (nasal NK/T-cell lymphoma) are the most commonly involved sites, but skin, the gastrointestinal tract, lung, testis, and soft tissues (extranasal NK/T-cell lymphoma) can be also affected \[[@CR52], [@CR53], [@CR56], [@CR58]\].

The prognosis of extranodal NK/T-cell lymphoma is poor, the worst among the PTCL categories \[[@CR57]•\]. The survival rate is 30% to 40%, with some differences between nasal and nonnasal disease; the nonnasal disease is more aggressive \[[@CR56], [@CR57]•, [@CR59]\]. The inclusion of radiotherapy in treatment protocols has improved the outcome of nasal NK/T-cell lymphoma in stage I or II \[[@CR55], [@CR56], [@CR57]•, [@CR60], [@CR61]\]. Among nasal forms, adverse prognostic factors are unfavorable IPI, advanced-stage disease (stage III or IV), high circulating EBV DNA levels, and detection of EBV in bone marrow cells by in situ hybridization \[[@CR56], [@CR57]•, [@CR60], [@CR62]--[@CR66]\]. Some studies suggest that a high proportion of large/transformed cells in the tumoral population has a negative impact on survival, but the significance of cytologic features as a prognostic indicator is still uncertain \[[@CR55], [@CR56], [@CR57]•, [@CR58]\]. Primary extranasal cases are highly aggressive and the response to therapy is poor even in patients with localized disease \[[@CR56], [@CR57]•\].

A Korean group has proposed a new prognostic index specifically developed for NK/T-cell tumors, based on four parameters: B symptoms, LDH levels, stage, and regional lymph node involvement. This index demonstrated better prognostic stratification of NK/T-cell lymphomas than the IPI \[[@CR54]\].

In addition, a recent study showed that four factors (nonnasal type, stage, performance status, and extranodal involvement) were significant prognostic factors in NK/T-cell lymphomas \[[@CR67]\]. Using these four variables, an NK prognostic index was successfully constructed in which the 4-year OS was 55% for patients with no adverse factors, 33% with one adverse factor, 15% with three factors, and 6% with four factors \[[@CR67]\].

Conclusions {#Sec7}
===========

PTCLs have long represented an orphan pathology, as explained by their relatively low incidence (though higher than the incidence of a "common" tumor such as Hodgkin's lymphoma), the difficulties encountered in their analysis, and their dismal prognosis. During the past few years, however, a great deal of interest has developed and new light has been shed on the pathobiology of these tumors, and leading to the proposal of more effective prognosticators. Although the IPI is somewhat effective for PTCL prognostication, more refined and possibly disease-specific novel scores have been explored. Several models including clinical-pathological and molecular features have been proposed and are now being validated. In addition, innovative therapeutic schedules have been proposed on the basis of newly developed microarray techniques. We seem close to the morning of a new era in which the shadows that have wrapped PTCLs for several decades will be dissipated.
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